- POSITIVE
Annual Revenue Amwill Health Care Mar-2026 Annual Revenue is Rs 48 Cr which is growth of 17.3% YoY.
- POSITIVE
Annual Net Profit Amwill Health Care Mar-2026 Annual Net Profit is Rs 11 Cr which is growth of 6.4% YoY.
Amwill Healthcare was established on August 21, 2017. The company specializes in derma-cosmetic product development, focusing on dermatological, cosmeceutical, and aesthetical solutions. It collaborates with contract manufacturers, distributors, and third-party agencies, outsourcing key functions for efficient execution
| Bidding Dates |
|---|
| 05 Feb 2025 - 07 Feb 2025 |
| Subscription |
|---|
| 5.49x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹126,000 | 1 | 1 | 1200 | 5.4 M | ₹105 - ₹111 | 70.65 % | ₹567.4 M - ₹599.8 M | RHP DOC |
Amwill Health Care IPO SUBSCRIPTION STATUS
07 Feb '25Total5.49x
Retail Individual Investor4.53x
HNI (NII) Investors5.5x
Qualified Institutional Buyers7.4x
Amwill Health Care IPO overall subscription rate was 5.49 times the total available shares
Amwill Health Care IPO retail subscription rate was 4.53 times in the retail segment
Amwill Health Care IPO non-institutional investor subscription rate was 5.5 times in the non-institutional investor category
Amwill Health Care IPO Qualified Institutional Bidder subscription rate was 7.4 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 40% | 40% | 20% |
07 Feb 2025 (Day 3) | 4.53x | 5.5x | 7.4x |
06 Feb 2025 (Day 2) | 1.64x | 0.57x | 2.08x |
05 Feb 2025 (Day 1) | 0.95x | 0.49x | 2.08x |
Amwill Health Care FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| H1FY25 | 65.2 | 231.6 | 101.5 | 97.7 | 38.2% |
| FY24 | 125.4 | 439.5 | -30.6 | -38.9 | 37.9% |
| FY23 | 31.1 | 301.7 | 47.9 | 44.8 | 14.2% |
| FY22 | 25.7 | 276.1 | 30.2 | 29.6 | 13.3% |
Amwill Health Care IPO SUBSCRIPTION STATUS DETAILS
Amwill Health Care had 5.4 M shares on offer
Amwill Health Care IPO offer price was in the range ₹105 - ₹111
Amwill Health Care IPO minimum Investment was ₹126000
Amwill Health Care IPO issue size was ₹ 567.4 M - ₹ 599.8 M
Amwill Health Care had a minimum lot size of 1200 Shares per application
Amwill Health Care NUMBER OF SHARES ON OFFER
Total5.4 M
Fresh Issue4.4 M
Offer for Sale1.0 M
Post Issue Promoter Holding %70.65 %
Amwill Health Care IPO IMPORTANT DATES
| Issue Open Date | 05 Feb 2025 |
| Issue close Date | 07 Feb 2025 |
| Allotment Date | 10 Feb 2025 |
| Refund Date | 11 Feb 2025 |
| Demat Account Credit Date | 11 Feb 2025 |
| Listing Date | 12 Feb 2025 |
| Listing on Exchange(s) | BSE |
| Amwill Health Care Allotment Status | Exchange |
Amwill Health Care IPO subscription opened on 05 Feb 2025, and closed on 07 Feb 2025
IPO allotment for Amwill Health Care was finalized on Monday, 10 Feb 2025
IPO listing for Amwill Health Care was on BSE on Wednesday, 12 Feb 2025
Amwill Health Care IPO LISTING GAINS
| Issue Price (adjusted) | 111.0 |
| Listing Open Price | 88.8 |
| Listing Close Price | 93.3 |
| Listing Gain% | -19.9% |
| Current Gain% | -63.1% |
Amwill Health Care Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amwill Health Care Ltd. | 41 | 82 | 7.2 | 1.1 | 1.7 | 14.2 | 13.2 | 48.4 | 17.3 | 11.4 | 6.4 | 5.7 | 6.4 |
| Sun Pharmaceutical Industries Ltd. | 1777.7 | 426529.8 | 38.9 | 7.9 | 6.9 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 45.7 | 4.9 |
| Divi's Laboratories Ltd. | 9780 | 259628.3 | 88.8 | 3.3 | 23.1 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4613.4 | 175478.9 | 82.6 | -110.5 | 10.1 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 55.8 | -0.7 |
| Laurus Labs Ltd. | 2405.5 | 129972.1 | 97 | 1 | 16.6 | 16.8 | 8.4 | 6861.3 | 22.2 | 888.8 | 148 | 24.8 | 95.9 |
| Zydus Lifesciences Ltd. | 1245.5 | 125326.4 | 27.8 | -17.9 | 4.4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
Annual
Balance Sheet
Ratios
Cash Flow
Amwill Health Care annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
16.9% | 21.9% | 48.4 | 41.3 | 44.3 | 30.3 | 27.6 | 18 | ||
Operating Exp. Ann. | 7.9% | 11.3% | 32.5 | 28.9 | 27.3 | 25.9 | 24 | 19 | |
Operating Profit Ann. | 44.6% | - | 13 | 11.7 | 16.7 | 4.3 | 3.7 | -1 | |
OPM Ann. % | 23.7% | - | 26.84% | 28.22% | 37.64% | 14.19% | 13.25% | -5.69% | |
8.2% | 11.7% | 33.1 | 29.4 | 27.5 | 26.1 | 24.3 | 19 | ||
EBITDA Ann. | 53.5% | - | 15.9 | 12.4 | 17 | 4.4 | 3.7 | -1 | |
EBITDA Ann. margin % | 31.2% | - | 32.87% | 29.93% | 38.39% | 14.57% | 13.26% | -5.69% | |
Interest Ann. | - | - | |||||||
Depr. | 44.2% | - | 0.6 | 0.5 | 0.2 | 0.2 | 0.3 | 0 | |
PBT Ann. | 54.2% | - | 15.4 | 11.9 | 16.8 | 4.2 | 3.3 | -1 | |
Tax Ann. | 52.5% | - | 3.9 | 1.2 | 4.3 | 1.1 | 0.8 | -0 | |
54.4% | - | 11.4 | 10.7 | 12.5 | 3.1 | 2.6 | -1 | ||
Net Profit Ann. | 54.4% | - | 11.4 | 10.7 | 12.5 | 3.1 | 2.6 | -1 | |
NPM Ann. % | 34.5% | - | 25.10% | 26.44% | 28.44% | 10.32% | 9.32% | -5.54% | |
EPS Adj. latest Ann. | 52.7% | - | 5.7 | 5.4 | 6.3 | 1.6 | 1.3 | -0.5 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
17.2%
2Y CAGR
4.5%
3Y CAGR
16.9%
5Y CAGR
21.9%
Total Revenue Annual growth is stable compared to historical averages.
Net Profit Ann.
1Y CHG
6.5%
2Y CAGR
-4.5%
3Y CAGR
54.4%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
12.5%
2Y CAGR
9.1%
3Y CAGR
7.9%
5Y CAGR
11.3%
Operating Expenses Annual Cr growth is higher than historical averages.
Amwill Health Care INFORMATION ON IPO ISSUE
About Amwill Health Care
Amwill Healthcare was established on August 21, 2017. The company specializes in derma-cosmetic product development, focusing on dermatological, cosmeceutical, and aesthetical solutions. It collaborates with contract manufacturers, distributors, and third-party agencies, outsourcing key functions for efficient execution
Object of the Issue
- Funding of working capital requirements of the company
- Marketing and brand building activities
- General corporate purposes
Amwill Health Care - PROMOTERS
| Name |
|---|
| Anand Gandhi |
| Tarun Gandhi |
Amwill Health Care Lead Manager of the Issue
Unistone Capital Private Limited
mb@unistonecapital.com
Amwill Health Care Registrar to the issue
ipo@bigshareonline.com
ipo@bigshareonline.com
Amwill Health Care Strengths
Asset-light business model
The company follows a scalable, asset-light business model by outsourcing key operations like manufacturing, prototype development, testing, and distribution. This approach allows a stronger focus on product formulation, development, marketing, and sales while fostering strategic partnerships for efficient execution
Strength
Extensive product portfolio
The company is a derma-cosmetic developer with a diverse portfolio and a unique product development model. It focuses on advanced formulations for higher efficacy and targeted solutions for specific dermatological concerns
Strength
High quality product development
The company ensures formulation quality by testing final products through contract manufacturers for molecular composition, texture, feel, and fragrance. Prototypes are also analyzed by dermatologists for pre-approval and effectiveness
Strength
Amwill Health Care Risks
Depend on developing derma-cosmetic products
The company's success relies on its ability to develop problem-solving derma-cosmetic products. A limited product portfolio since inception may restrict innovation, potentially impacting revenue and profitability
Risk
Depend on sale of limited products
The company relies on a few key products for a significant portion of its revenue. Any decline in sales volume, pricing, or inability to sell these products could negatively impact its business, financial condition, cash flows, and results of operations
Risk
Risk of demand
Failure to adapt to market trends, changing customer preferences, or maintain brand reputation could reduce product demand, impacting business growth and revenue
Risk
IPO FAQs
This IPO consists of an offer for sale of up to Rs 11.1 crore, of 1,000,000 shares. It also consists of a fresh issue of Rs 48.9 crore.
The promoters of the company are Anand Gandhi and Tarun Gandhi.
The category allocation of qualified institutional buyers is 20.0%, the category allocation of non individual investors or high networth individuals is 40.0% and for retail investors it is 40.0%.
The price band of the IPO is Rs 105.0 - 111.0.
The IPO application opens on Feb 05, 2025 and closes on Feb 07, 2025.
The minimum lot size for the IPO is 1200. The maximum lot size for the IPO is 1200.
For all category investors, the minimum application amount for this IPO is Rs. 126,000.0, the maximum value for this IPO is Rs 133,200.0.
This IPO will be allotted on Feb 10, 2025.
The refund will be credited to your account on Feb 11, 2025.
The allotted shares will be credited to your demat on Feb 11, 2025.
Amwill Healthcare Ltd.’s shares listed on the stock exchanges on Feb 12, 2025.